Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne .

Property Value
dbo:abstract
  • Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne . In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values . (en)
dbo:industry
dbo:location
dbo:numberOfEmployees
  • 24 (xsd:integer)
dbo:type
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2020-01-17 10:53:26Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 39607222 (xsd:integer)
dbo:wikiPageLength
  • 2202 (xsd:integer)
dbo:wikiPageModified
  • 2020-01-17 10:53:23Z (xsd:date)
dbo:wikiPageOutDegree
  • 11 (xsd:integer)
dbo:wikiPageRevisionID
  • 936209524 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne . (en)
rdfs:label
  • Catabasis Pharmaceuticals (en)
owl:sameAs
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Catabasis Pharmaceuticals (en)
is foaf:primaryTopic of